Nonprofit drug developer TB Alliance announced today that it will partner with an Indian company to manufacture and commercialize pretomanid for treating extensively drug-resistant tuberculosis (XDR-TB).
In its weekly flu update today, the US Centers for Disease Control and Prevention (CDC) reported the first pediatric flu deaths of the new season and noted that the nation's flu activity increased slightly last week but is still at low levels.
A new study in Infection Control and Hospital Epidemiology describes several cases of colistin-resistant Klebsiella pneumoniae infections at a hospital in northern India.
According to the World Health Organization's (WHO's) Ebola dashboard today, officials in the Democratic Republic of the Congo (DRC) confirmed 2 new cases of Ebola in a 14-month-long outbreak in that country, raising the total to 3,250 infections.
As reported yesterday, 117 of the cases are considered probable infections. The DRC's Ebola technical committee (CMRE) has not yet posted information on the four new cases described yesterday.
In its latest weekly update, the Global Polio Eradication Initiative (GPEI) said today that Pakistan recorded three new cases of wild poliovirus type 1 (WPV1) this week, and the Democratic Republic of the Congo (DRC) and the Central African Republic recorded new cases of vaccine-derived poliovirus type 2 (cVDPV2).
Doctors Without Borders/Médecins sans Frontières (MSF) is calling on drug maker Johnson & Johnson to lower the price of bedaquilin, an oral medication for the treatment of patients with multidrug-resistant tuberculosis (MDR-TB).
A survey of Israeli physicians and analysis of patient data has found that antibiotics are overused in patients with end-of-life advanced directives, Israeli researchers reported today in Infection Control and Hospital Epidemiology.
A 10-year analysis of US tuberculosis (TB) data shows that, for children and adolescents, incidence is low and steadily dropping, but rates are disproportionately high in some groups. Researchers from the Centers for Disease Control and Prevention (CDC) reported their findings yesterday in The Lancet Public Health.
The shorter, simpler regimen with the new drug is poised to improve treatment against a difficult disease and to lower costs.
An investigational drug to treat highly resistant strains of tuberculosis (TB) took another step in the regulatory approval process yesterday.
